drug · vaccine component
respiratory syncytial virus vaccine
Phase 2updated 6mo agoby $MRNA Moderna, Inc.🔗 ChEMBL
Phase 2community read0 votes
Vaccine component drug with a maximum clinical stage of Approval, with an approval for respiratory syncytial virus infection.
targets
Fusion glycoprotein F0
all catalysts(0)
nothing on the calendar yet
Trials studying respiratory syncytial virus vaccine
News(5)
- Moderna enjoys stable vaccine sales thanks to global COVID uptakeWhile Moderna preps an entry to the oncology market next year with a personalized cancer vaccine, COVID sales are holding steady with several other vaccine launches underway around the world.biospace · 8d ago
- Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting gameLilly’s better-than-expected results allayed concerns — for now — over GLP-1 pricing pressure. Elsewhere, Novartis withstood a tumultuous quarter and GSK battled investor angst.biopharma_dive · 15d ago
- GSK vaccine sales miss expectations amid falling demand from adultsWith pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.biospace · 17d ago
- GSK plans 1.2K+ layoffs at Belgium sites as $2.5B restructure gains momentumThe layoffs across GSK’s Belgium sites come on the heels of the pharma’s planned shuttering of its German vaccine manufacturing site, which prompted job cuts for about 650 employees.biospace · 1mo ago
- GSK lays off 650 staffers amid closure of German vaccine manufacturing siteGSK is consolidating its vaccine manufacturing operations to one site—located in Canada—amid the pharma’s recent $2.5 billion savings campaign.biospace · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that